Strand Genomics Announces Availability Of Technology Solutions To Power Expansion Of Personalized Medicine Centers In U.S.

Strand Genomics, Inc. (Strand) recently announced its recent unveiling of a full suite of technology solutions that will support its expansion of Strand Centers for Genomics & Personalized Medicine (Strand Centers) into the U.S. At last month’s ACMG 2014 Annual Clinical Genetics Meeting in Nashville, Strand demonstrated how its StrandOmics and Avadis-NGS Server Edition software support the end-to-end clinical genomics services that will be offered by Strand Centers as the company seeks to expand its successful model from India into the United States.

Updated CME Program Is Designed To Help Clinicians Reduce Heart Failure Patient Hospital Readmissions

Critical Diagnostics recently announced that an updated accredited, self-learning program entitled, “Reducing Heart Failure Readmissions: Case Studies Utilizing Biomarkers for Risk Stratification,” is available now online at www.heartfailurecases.com.

New Global Initiative Aims to Improve Patient Outcomes in Metastatic Colorectal Cancer

Merck Serono, the biopharmaceutical division of Merck, recently announced the formation of the global Oncology Partnership and Education Network (OPEN). This global initiative, supported by Merck Serono, brings together a multidisciplinary group of stakeholders involved with the management of cancer to help improve patient care. Focusing on metastatic colorectal cancer (mCRC) as its first priority, OPEN aims to reinforce the important role biomarker testing has in personalizing care in mCRC. The launch of OPEN coincides with Colorectal Cancer Awareness Month in many countries.

SysQuant – Pancreatic Cancer Study in PLOS ONE

The SysQuant® study addressing pancreatic cancer published recently in PLOS ONE provides a helicopter view over cell signalling pathways that elegantly demonstrates Proteome Sciences ability to measure the phosphorylation status and expression of very important drug targets and many other signalling proteins. This technology is equally applicable to all cancers. With our collaborators at King’s College Hospital, London SysQuant® identified a number of novel potential therapeutic targets and new diagnostic and prognostic biomarkers covered by patent applications.

Industry-Academic Collaboration Targets Major Proteomics Quantitation Advances using Proteome Sciences’ proprietary TMT Technology

Scientists working to discover protein-based biomedical breakthroughs are constrained by the time and cost required to identify and quantify large numbers of proteins. Thermo Fisher Scientific and researchers at Harvard Medical School have teamed up to develop promising new ways to perform protein quantitation on a much larger scale than currently possible, with the goal of accelerating discovery of effective therapies.